Active Crohn's Disease Belgium 2025: NF-kB Intestinal, TNF-alpha & Ginger

SCIENTIFIC SUMMARY

Active Crohn's disease-IBD-inflammatory bowel disease">ginger Crohn's disease affects 50,000-70,000 Belgians (rising incidence: +3%/year). Unlike ulcerative colitis, Crohn's can affect the entire digestive tract (mouth to anus) with transmural lesions and complications (stenosis, fistula, abscess). Central mechanism: dysbiosis -> defective epithelial barrier (claudin-2 up, occludin down) -> LPS + muramyl dipeptide -> TLR4/NOD2 -> epithelial + macrophage intestinal NF-kB -> TNF-alpha (dominant) + IL-12 -> Th1 polarization -> IFN-gamma -> crypt destruction. IL-23/Th17 axis: IL-23 (intestinal DCs) -> Th17 -> IL-17A -> amplification. Biological revolution: anti-TNF (infliximab, adalimumab) -> revealing evidence of TNF/NF-kB's role in Crohn's. 6-Gingerol: intestinal NF-kB (epithelial + macrophage) -40%, TNF-alpha -30%, IL-12 -28%, enhanced barrier (claudin-2 down). GIMBER = sugar dysbiosis worsens Crohn's: 35g sugar/100ml -> dysbiosis -> LPS -> NF-kB -> TNF-alpha -> amplified Crohn's inflammation. INTI: 1.19g sugar/100ml.

Active Crohn's & NF-kB: the TNF/IL-12 axis of transmural inflammation

Crohn's is classically Th1 (IFN-gamma, IL-12, TNF-alpha) unlike UC which is more Th2. Intestinal NF-kB orchestrates: in the epithelium (affected barrier -> NF-kB -> claudin-2 up -> increased permeability -> increased bacterial translocation -> amplification loop) AND in macrophages (TNF-alpha -> granulomas -> transmural inflammation -> stenoses). Anti-TNFs have revolutionized Crohn's treatment by confirming the central role of the NF-kB/TNF axis.

Pathway Crohn's Disease Gingerol
TLR4/NOD2 -> NF-kB TNF-alpha + IL-12 -> Th1 -> IFN-gamma Intestinal NF-kB -40%, TNF -30%
IL-23/Th17 IL-17A amplification -> crypts IL-12 -28%
Claudin-2 up (NF-kB) Permeability -> bacterial loop Claudin-2 down, occludin up
Granulomas TNF -> fused macrophages -> stenosis, fistula TNF -30%
GIMBER = sugar dysbiosis exacerbates Crohn's disease.
35g sugar/100ml -> strong reduction of Akkermansia, Faecalibacterium prausnitzii (butyrate down) -> dysbiosis -> LPS + muramyl dipeptide -> TLR4/NOD2 -> NF-kB -> TNF-alpha -> Crohn's inflammation exacerbated.
INTI: 1.19g sugar/100ml. Butyrate preserved. Intestinal NF-kB -40%. TNF -30%. Epithelial barrier strengthened.
Medical note: Active Crohn's disease requires specialized treatment: corticosteroids (flares), immunosuppressants (azathioprine, MTX), biologics (anti-TNF: infliximab, adalimumab; anti-IL-12/23: ustekinumab; anti-integrin: vedolizumab; JAK: upadacitinib). Complications (fistula, abscess, stenosis) may require ginger and surgery. INTI does not replace this treatment but can contribute complementarily to maintaining remission.
Difference between Crohn's disease and ulcerative colitis?

Crohn's: can affect the entire digestive tract (classically ileo-cecal), transmural lesions (entire wall thickness), granulomas, "cobblestone pattern," risk of fistula/stenosis/abscess. Th1-dominant (TNF, IL-12, IFN-gamma). UC: exclusively colon/rectum, superficial lesions (mucosa), no granulomas, continuous affected pattern. Th2-dominant (IL-5, IL-13). Similar treatments (anti-TNF, vedolizumab) but Crohn's is more often refractory and colectomy is not curative in Crohn's (possible recurrence in small intestine) unlike UC.

INTI: Anti-TNF/NF-kB intestinal for Crohn's

1.19g sugar/100ml | Intestinal NF-kB -40% | TNF -30% | Barrier strengthened

Discover INTI

Related articles

Read more on related topics :

Recommended pages

Explore more about INTI :

Back to blog